Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP EBITDA Margin

EBITDA as a percentage of revenue.

Simulations Plus, Inc.NASDAQ: SLP

EBITDA Margin · Q2 FY2026 · quarter ended Feb 2026

EBITDA Margin widens to 30.6%

EBITDA Margin was 30.6% in Q2 FY2026, up 4.8 pp from a year earlier. On a trailing-twelve-month basis it was 21.5%, up 0.4 pp year over year. Over 3 fiscal years it narrowed by 16.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 34.8% for the fiscal year ending Aug 2026, up from 18.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterFeb 2026
30.6%+18.0 pp QoQ
Last fiscal yearAug 2025
18.6%-7.2 pp YoY
LTMFeb 2026
21.5%+0.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.8 pp+0.4 pp-4.4 pp
1 year-7.2 pp+16.3 pp+23.5 pp
3 years-16.1 pp+15.1 pp+31.2 pp
5 years+17.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
18.6%
Year-over-year change
-7.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SLP compares with its peers on the latest reported figures

  • SLP's LTM Feb 2026 EBITDA Margin of 21.5% is the highest of the 10 companies compared; the peer median is -75.1%.
  • Its year-over-year change of +0.4 pp is the 3rd highest of 10, against a peer median of -6.9 pp.
  • Over three fiscal years its change of -16.1 pp compares with a peer median of -6.9 pp.
SLP Competitors Peer median
EBITDA Margin for SLP and competitors
Company Period LTM level YoY 3-year change
SLPSimulations Plus, Inc.LTM Feb 202621.5% +0.4 pp-16.1 pp
NRCNational Research CorporationLTM Mar 202620.1% -9.1 pp-10.5 pp
OPRXOptimizeRx CorporationLTM Mar 202617.6% +23.8 pp+30.2 pp
DHDefinitive Healthcare Corp.LTM Mar 20264.9% +295.3 pp-78.9 pp
AGLAgilon Health, Inc.LTM Mar 2026-5.9% -2.2 pp-3.2 pp
CLLSCellectis S.A.LTM Mar 2026-75.1% -6.9 pp+343.8 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 2026-81.4% -6.3 pp+87.8 pp
ACIUAC Immune S.A.LTM Mar 2026-1740.8% -1565.2 pp-167.5 pp
KRROKorro Bio, Inc.LTM Mar 2026-2034.0% -137.9 pp—
NAKANakamoto Inc.LTM Mar 2026-7060.9% -6900.9 pp-2402.8 pp
ANROAlto Neuroscience, Inc.FY2025— ——
Peer median (excluding SLP) -75.1%-6.9 pp-6.9 pp

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Revenue46.47M53.91M59.58M70.01M79.18M
Cost of Revenue10.6M10.82M11.63M26.86M32.96M
Gross Profit35.87M43.08M47.95M43.15M46.22M
Gross Margin77.2%79.9%80.5%61.6%58.4%
Research & Development4.05M3.21M4.5M5.75M6.88M
Selling, General & Admin20.57M24.97M34.72M31.27M32.85M
Operating Expenses24.61M28.17M39.22M37.02M116.95M
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
EBITDA14.7M18.69M13.07M18.08M14.7M
EBITDA Margin31.6%34.7%21.9%25.8%18.6%
Operating Income11.25M14.91M8.73M6.13M(70.73M)
Operating Margin24.2%27.7%14.6%8.8%-89.3%
Interest Income201K717K4.13M4.38M722K
Interest Expense22K0000
Other Income / Expenses(168K)204K2.97M6.28M1.35M
Income Before Tax11.09M15.12M11.7M12.41M(69.38M)
Pre-Tax Margin23.9%28.0%19.6%17.7%-87.6%
Income Tax Expense1.3M2.63M1.73M2.46M(4.66M)
Net Income9.78M12.48M9.96M9.95M(64.72M)
Net Margin21.1%23.2%16.7%14.2%-81.7%
EPS (Basic)0.490.620.500.50(3.22)
EPS (Diluted)0.470.600.490.49(3.22)
Weighted Avg Shares20.05M20.2M20.08M19.99M20.1M
Weighted Avg Shares (Diluted)20.74M20.75M20.47M20.3M20.1M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.